for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Teijin Ltd

3401.T

Latest Trade

2,110.00JPY

Change

0.00(0.00%)

Volume

51,800

Today's Range

2,095.00

 - 

2,113.00

52 Week Range

1,652.00

 - 

2,211.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2,110.00
Open
2,098.00
Volume
51,800
3M AVG Volume
17.72
Today's High
2,113.00
Today's Low
2,095.00
52 Week High
2,211.00
52 Week Low
1,652.00
Shares Out (MIL)
191.83
Market Cap (MIL)
426,392.30
Forward P/E
10.79
Dividend (Yield %)
2.79

Next Event

Q3 2020 Teijin Ltd Earnings Release

Latest Developments

More

Teijin And Neurosigma Enter Into Exclusive License Agreement

Continental Structural Plastics Acquires Ami Stamping, Manchester Operations

Teijin Ltd - To Sell Entire Stake In Consolidated Subsidiaries Of Teijin Film Solutions Limited (“Tfs”) And P.T. Indonesia Teijin Film Solutions (“Itfs”), That Operate Polyester Film Businesses

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Teijin Ltd

TEIJIN LIMITED is a Japan-based company engaged in aramid, carbon fiber, resin, composite molding material, fiber, medicine, and information technology (IT) business. The Company operates in two business segments. The Materials segment is involved in the manufacture and sale of aramid fibers, carbon fibers, polycarbonate resins, polyester films, polyester fibers, textile products, and composite molding materials. The Healthcare segment is involved in the manufacture and sale of pharmaceuticals and medical devices, as well as the provision of home medical services. The Company is also engaged in IT related business, such as the operation and development of information systems, the maintenance and engineering business, as well as the design and sale of plants and equipment.

Industry

Textiles - Non Apparel

Contact Info

Kasumigaseki Common Gate West Tower

3-2-1, Kasumigaseki

+81.3.35064529

https://www.teijin.co.jp/

Executive Leadership

Jun Suzuki

Executive President, Chief Executive Officer, Representative Director

Kazuhiro Yamamoto

Executive Vice President, Chief Financial Officer, Representative Director

Yasumichi Takesue

Senior Managing Executive Officer, Director

Hiroshi Uno

Senior Managing Executive Officer, Director

Yoshihisa Sonobe

Managing Executive Officer, Director

Key Stats

3.20 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.7K

2018

0.8K

2019

0.9K

2020(E)

0.9K
EPS (JPY)

2017

254.910

2018

231.260

2019

232.390

2020(E)

199.660
Price To Earnings (TTM)
13.89
Price To Sales (TTM)
0.48
Price To Book (MRQ)
1.02
Price To Cash Flow (TTM)
4.94
Total Debt To Equity (MRQ)
98.23
LT Debt To Equity (MRQ)
58.96
Return on Investment (TTM)
4.69
Return on Equity (TTM)
3.21

Latest News

Latest News

BRIEF-SanBio and Teijin to terminate licensing agreement regarding SB623 for stroke treatment

* Says co and Teijin Limited would terminate the exclusive licensing agreement signed in 2009, regarding the development and marketing of SB623 for stroke treatment in Japan

BRIEF-Teijin To Invest 35 Billion Yen To Build Carbon Fiber Plant In U.S. -Nikkei

* TEIJIN TO INVEST 35 BILLION YEN TO BUILD CARBON FIBER PLANT IN U.S. -NIKKEI Source text: (http://s.nikkei.com/2Al5U6z) Further company coverage:

BRIEF-Teijin to merge with fiber unit

* Says it will merge with a Tokyo-based fiber consolidated subsidiary

BRIEF-R&I affirms Teijin's rating at "A-" and says stable outlook -R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A-" -R&I

BRIEF-Teijin lowers conversion price for 2018 due euro-yen denominated convertible bonds and 2021 due euro-yen denominated convertible bonds

* Says it lowered the conversion price for 2018 due euro-yen denominated convertible bonds to 2,026 yen per share, from 2,035.7 yen per share, after Oct. 1

BRIEF-Merz, Teijin announce partnership to bring Xeomin to Japan

* Merz and Teijin announce partnership to bring Xeomin (Incobotulinumtoxina) to Japan

BRIEF- Teijin to transfer rights and obligations to unit TEIJIN FRONTIER

* Says it will transfer rights and obligations, including inventories, investment securities and capital invested into group company, to wholly owned unit TEIJIN FRONTIER CO., LTD.

BRIEF- JCR Pharmaceuticals to develop allogeneic regenerative medical product using DPCs with Teijin

* Says it entered into co-development and license agreement with Teijin Ltd, regarding JTR-161, an allogeneic regenerative medical product using dental pulp stem cells (DPCs) for the indication of acute cerebral infarction (stroke) for Japan, on July 18

BRIEF-Teijin invests in its twaron capacity in Dutch production facility

* Teijin invests in its twaron capacity in Dutch production facility

BRIEF-Radius Health announces license and development agreement for Abaloparatide-Sc with Teijin Limited in Japan

* Radius Health announces license and development agreement for Abaloparatide-Sc with Teijin Limited in Japan

BRIEF-Teijin lowers conversion price for 2018 due euro-yen denominated convertible bonds and 2021 due euro-yen denominated convertible bonds

* Says it lowered the conversion price for 2018 due euro-yen denominated convertible bonds and 2021 due euro-yen denominated convertible bonds to 2,035.7 yen per share and 2,001.3 yen per share respectively, from 2,063.5 yen per share and 2,028.6 yen per share, effective...

BRIEF-Teijin to sell US-based home healthcare units

* Says it plans to sell 100 percent stake of shares in its two US-based home healthcare units Braden Partners, L.P and Associated Healthcare Systems, Inc, on April 27 (US local time)

BRIEF-Japan's Teijin planning $18 mln air bag fabric plant in Vietnam - Nikkei

* Japan's Teijin planning $18 million air bag fabric plant in Vietnam - Nikkei Source text for Eikon: Further company coverage:

BRIEF-Nativis enters into licensing agreement for Glioblastoma Multiforme in Japan

* Nativis enters into exclusive licensing agreement for Glioblastoma Multiforme in Japan

BRIEF-Takiron to sell part of medical business to Teijin Ltd

* Says the co plans to set up new unit on July 3, to take over part of medical business from the co

BRIEF-Teijin adjusts conversion prices for 2018 due and 2021 due euro-yen denominated convertible bonds with warrants

* Says it adjusted the conversion price for 2018 due euro-yen denominated convertible bonds to 2,063.5 yen per share, from 2,069.0 yen per share, effective Oct. 1

BRIEF- R&I affirms Teijin Ltd's rating at "A-" and announces stable outlook -R&I

* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A-" -R&I

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up